1. Introduction {#s0005}
===============

Migraine is a highly debilitating and socioeconomically costly neurological disorder, affecting 16% of the population worldwide ([@bb0155]; [@bb0225]). Despite intensive research during the past several decades, the neurobiological basis and pathophysiology of migraine remains largely unknown. Serotonin (5-hydroxytryptamine, 5-HT) has been directly implicated in the pathophysiology of migraine ([@bb0090]) and studies on plasma and urinary levels of 5-HT and its main metabolite, 5-hydoxyindoleacetic acid (5-HIAA) suggest that between their migraine attacks, patients have decreased levels of plasma 5-HT ([@bb0060]; [@bb0200]). Accordingly, although plasma levels of 5-HT do not necessarily reflect brain 5-HT levels, migraine has been considered a syndrome of chronically low brain 5-HT levels. Several studies have attempted to assess brain 5-HT levels in migraine patients, but results have been equivocal, showing both higher and lower levels compared to controls ([@bb0050]). We here use a novel neuroimaging method to investigate if migraine is a syndrome associated with low 5-HT brain levels.

The 5-HT~4~ receptor, one of 14 5-HT receptors, is inversely related to central serotonergic tonus and can thus be used as an indirect biomarker of brain 5-HT levels. In rats, brain 5-HT~4~ receptor binding decreased after 14 days of selective 5-HT reuptake inhibitor (SSRI) administration ([@bb0115]). In humans, carriers of the short allele of the 5-HT transporter (5-HTT) gene, which is associated with relatively increased synaptic 5-HT levels, had lower neocortical 5-HT~4~ receptor binding compared to carriers of the long allele ([@bb0065]). Furthermore, the final support for the 5-HT~4~ receptor being inversely related to brain 5-HT levels, came from a study showing that three weeks of SSRI intervention led to a significant decrease in brain 5-HT~4~ receptor binding in humans ([@bb0085]).

Here we investigated differences in brain 5-HT levels between migraine patients without aura and controls using PET imaging of the 5-HT~4~ receptor as an in vivo biomarker of brain 5-HT levels. According to existing beliefs, we hypothesized that migraine patients had higher 5-HT~4~ receptor binding compared to controls.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

Participants were recruited through a Danish website for recruitment of volunteers to health research and from a local database. All patients fulfilled the following inclusion criteria: 1) 18--65 years old, 2) a verified diagnosis of migraine without aura according to the International Headache Society Criteria ([@bb0210]). 3) at least one migraine attack every other month but less than five migraine days per month, 4) self-reported previous effect of treatment of migraine attacks with sumatriptan (a 5-HT~1B/1D~ receptor agonist drug). The last criterion was applied, since the subjects were also included in a study investigating the 5-HT~1B~ receptor ([@bb0055]). A standardized interview of all patients was conducted at screening including the following items: duration of disease (years), duration of attack when untreated (hours), migraine days pr. month, frequency of attack (number per month), maximum pain intensity of untreated headache as measured with the Numerical Rating Scale (NRS) (number 0--10), intake of acute pain medication including triptans (days per month), and date of their last migraine attack. Inclusion criteria for age- and sex-matched controls included: 1) no history of migraine including probable migraine and no first-degree relatives with migraine. For all participants, the following exclusion criteria were applied: 1) a history of any other primary headache (except tension-type headache \<5 days per month), 2) psychiatric, cerebro- or cardiovascular disease, 3) contraindications for magnetic resonance imaging (MRI), 4) pregnancy or nursing, 5) daily intake of medication including migraine prophylaxis.

All subjects reported to be headache free on the day of their PET scan, and no medication intake was allowed for the last 24 h prior to the scan. All migraine patients were migraine free for at least 48 h prior to the PET scan. In addition, to ensure that all included subjects were truly between two migraine attacks, headache diaries were obtained from all patients for 48 h after the scan. All included participants had a normal physical and neurological examination and unremarkable brain MRI. All participants filled out the major depression inventory (MDI) on the day of the PET scan.

The study was approved by the Ethics Committee of The Region of Copenhagen (H-6-2014-057). In accordance with the Declaration of Helsinki of 1964, with later revisions, all participants gave written consent after detailed oral and written information about the study.

2.2. PET and MR imaging {#s0020}
-----------------------

Synthesis of the radioligand, \[^11^C\]SB207145, was performed using an automated radiosynthesis system as previously described ([@bb0145]). An intravenous bolus injection of the radioligand was given over 20 s, followed by 120-minute dynamic data acquisition with a high-resolution research tomography (HRRT) PET scanner (CTI/Siemens, Knoxville, TN, USA). To minimize head movement, all subjects had their head stabilized in a specialized head holder. The scans were reconstructed into 38 frames (6 × 5, 10 × 15, 4 × 30, 5 × 120, 5 × 300, and 8 × 600 s) using a 3D-OSEM-PSF algorithm (16 subsets, 10 iterations) with TXTV based attenuation correction (image matrix, 256 × 256 × 207; voxel size, 1.22 × 1.22 × 1.22 mm), as previously described ([@bb0095]; [@bb0100]; [@bb0230]). T1 and T2 weighted MRI scans used for co-registration were acquired for each subject using a Siemens Prisma 3T scanner (Siemens, Erlangen, Germany) with a 64-channel head coil.

2.3. Quantification of 5-HT~4~ receptor binding {#s0025}
-----------------------------------------------

Single-subject PET images were corrected for intra-scan movement by aligning the frames 10--38 to a reference frame (frame 26) using a scaled least-squares cost function in AIR 5.2.5. Co-registration and alignment of PET images to the corresponding T1-weighted MRI image was done using SPM8. Regions of interest (ROIs) were automatically delineated on each subject\'s MRI using PVElab software ([www.nru.dk](http://www.nru.dk){#ir0005}) as previously described ([@bb0235]). Accurate co-registration and ROI placement were confirmed by visual inspection for each subject, across all planes. Time activity curves (TAC) and grey matter volumes for each ROI were then extracted.

The Simplified Reference Tissue Model (SRTM) was applied to calculate the non-displaceable binding potential (BP~ND~) of \[^11^C\]SB207145. This model has previously been validated for quantification of \[^11^C\]SB207145 in the human brain ([@bb0145]). Cerebellum (excluding vermis) was used as a reference region since it has a negligible density of 5-HT~4~ receptors ([@bb0075]; [@bb0145]). Kinetic modeling was performed in MATLAB R2013a (8.1.0.604) 64 bit (Mathworks Inc., MA) using an in-house script and the person performing the kinetic modeling was blinded to group status (migraine patient or control). Parametric 5-HT~4~ receptor binding images for voxel based analysis were generated using PETSurfer (<http://surfer.nmr.mgh.harvard.edu>, version 6.0), as previously described ([@bb0080]). In summary, a combined volumetric and surface registration algorithm was used to normalize each single-subject structural T1 to Montreal Neurological Institute (MNI) space ([@bb0175]). After application to the co-registered PET-images, these were then volume-smoothed with a 6-mm full-width half-maximum 3D Gaussian kernel. The Multilinear Reference Tissue Model 2 (MRTM2), using cerebellum as reference region and high-binding regions (putamen, pallidum and caudate) for estimation of k~2~′, was applied to estimate voxel-level BP~ND~s.

2.4. Genotyping {#s0030}
---------------

Participants were genotyped for the tri-allelic 5-HT transporter-linked polymorphic region (5-HTTLPR) polymorphism. Briefly, genotyping was performed by PCR amplification from forward primer 5′-TAATGTCCCTACTGCAGCCC-3′ and reverse primer 5′-GGGACTGAGCTGGACAACC-3′. The fragments were then digested by the restriction enzyme MspI and separated by gel electrophoresis. Participants were categorized into two groups: 1. Carriers of the short allele (S-carriers) or the long L~G~ allele (L~G~-carriers). 2. Homozygotes of the long L~A~ allele (L~A~-homozygotes). This dichotomization was based on a previous study showing that carriers of the low-expressing alleles, S and L~G~ have lower neocortical 5-HT~4~ receptor binding compared to homozygotes of the high-expressing allele, L~A~ ([@bb0065]).

2.5. Experimental design and statistical analysis {#s0035}
-------------------------------------------------

This study was an observational, cross-sectional study comparing interictal migraine without aura patients (\>48 hour migraine free before and after the scan) with sex- and age matched controls. Sample size was based on a previous study showing that n = 15 is sufficient to detect a 15% difference between groups with a power of 0.80 in very large brain regions (\>50 cm^3^), such as e.g. neocortex ([@bb0150]). Differences between groups in demographics, genotypes and PET variables were evaluated using two-sample *t*-tests.

To evaluate differences in brain 5-HT levels between migraine patients and controls we used the BP~ND~ of a large neocortical region as a proxy of central serotonergic tonus. The neocortical BP~ND~ was chosen, since previous studies investigating brain 5-HT levels in migraine mostly focused on cortical regions (for review see ([@bb0050])). The cortical brain regions receive numerous serotonergic projections from the raphe nuclei and 5-HT plays an important role in the modulation of cortical activity ([@bb0030]). Additionally, the relationship between the 5-HTTLPR genotype and 5-HT~4~ receptor binding is most pronounced in neocortex ([@bb0065]).

The mean neocortical \[^11^C\]SB207145 BP~ND~ was calculated based on 11 neocortical brain regions (occipital cortex, orbitofrontal cortex, superior, medial and inferior frontal gyri, insula, superior, medial and inferior temporal gyri, sensory motor cortex and parietal cortex) by volume weighting grey matter segmented brain region BP~ND~\'s:$$\text{Neocortical}\ 5 - {HT}_{4}\ \text{receptor\ binding} = \Sigma\left\lbrack {5 - {HT}_{4}\ {BP}_{ND}\left( \text{region}_{x} \right) \ast \text{volume}\left( \text{region}_{x} \right)} \right\rbrack/\left\lbrack {\Sigma\ \left( {\text{volume}\left( \text{region}_{x} \right)} \right)} \right\rbrack$$

As our primary investigation, a general linear model including neocortical BP~ND~ as the primary dependent variable and group status (patients vs. controls) as the predictive variable was then used to model effects of group on neocortical 5-HT~4~ receptor binding. To this model, 5-HTTLPR-status (S or L~G~ carriers vs. L~A~ homozygotes), sex and age were added as covariates, since all are known to affect neocortical 5-HT~4~ receptor binding ([@bb0065]; [@bb0140], [@bb0125]). All subjects received tracer doses (injected mass of SB207145 \< 0.024 μg/kg) obviating the inclusion of injected mass a covariate ([@bb0130]). Effects of interaction between group and genotype were evaluated and excluded unless statistically significant. To detect any regional (including subcortical) specific group differences in 5-HT~4~ receptor binding, whole brain voxel-wise multiple regression was performed using the same linear model as in the primary analysis. Only voxels (sized 1 × 1 × 1 mm) with an average BP~ND~ \> 0.3 were evaluated within a whole brain mask. In addition, associations between measures of clinical severity (attack frequency, years with migraine and time since last migraine attack) and neocortical 5-HT~4~ receptor binding were evaluated in the patient group only using a general linear model including 5-HTTLPR-status, age and sex as co-variates.

Statistical tests were carried out using R Studio 3.2.3 and SPM8. We ensured that model assumptions were met by examination of quantile-quantile plots, distribution of the residuals, and predicted values plotted against residuals. In the ROI analyses, the significance threshold was set at p \< .05 (two-tailed). In the voxel based analysis, a p-value threshold of p \< .001 at voxel level was used. To correct for multiple comparisons only clusters at p \< .05 corrected using the family wise error rate (FWE) were assumed significant. All other p-values are reported without correction for multiple comparison.

3. Results {#s0040}
==========

3.1. Demographics and migraine characteristics {#s0045}
----------------------------------------------

Out of the 18 migraine patients who completed the study, three reported to have a migraine attack within 48 h after the PET scan. These were excluded from the primary analysis. Sixteen controls completed the study. One migraine patient (subject 15) was scanned for 90 instead of 120 min, because she felt anxious in the scanner. To ensure that this patient did not affect our results, we conducted the primary analysis both with and without this patient. Thus, data from 15 migraine patients and 16 controls were included in the primary analysis.

A summary of demographics and PET variables are presented in [Table 1](#t0005){ref-type="table"}. Clinical data of the migraine group is shown in [Table 2](#t0010){ref-type="table"}. The regional distribution of the tracer was in concordance with previous studies with lowest binding in neocortex and highest binding in striatum. We found no differences in grey matter volume or MDI score between the two groups and no interaction between group and genotype.Table 1Demographics and PET variables.Table 1PatientsControlsp-Value[a](#tf0005){ref-type="table-fn"}Number of subjects (men/women)15 (2/13)16 (3/13)Genotype (L~A~ homozygote/S or L~G~ carrier)6/96/10Age (years)29.6 ± 10.228.9 ± 10.2.85BMI (kg/m^2^)22.6 ± 1.723.9 ± 4.8.33Major depression inventory7.87 ± 7.67.13 ± 4.8.75Injected radioactivity (MBq)584 ± 16591 ± 19.34Specific radioactivity (GBq/μmol)567 ± 282486 ± 217.38\[^11^C\]SB injected mass per kg (μg/kg)0.008 ± 0.0060.008 ± 0.005.90\[^11^C\]SB cerebellum AUC/specific radioactivity (GBq/μmol)31.1 ± 2332.6 ± 21.85[^2][^3]Table 2Migraine history.Table 2SubjectMigraine history\
(years)Attack frequency\
(n/month)Time since last migraine attack (days)1821727212321311425122515215620131719119880.550917215107129116310122271336441416351510213Median (range)15 (2--36)2 (0.5--4)15 (4--50)

3.2. Differences in neocortical binding {#s0050}
---------------------------------------

We found that migraine patients had significant lower neocortical \[^11^C\]SB207145 binding compared to controls (0.60 ± 0.09 (mean ± SD) vs. 0.67 ± 0.05 (mean ± SD), p = .024) ([Fig. 1](#f0005){ref-type="fig"}) after adjustment for covariates. This difference remained after excluding subject 15 (0.63 ± 0.06 vs. 0.68 ± 0.05, p = .038). Post hoc explorative analysis of the ROIs included in the neocortical region showed that the low binding was most pronounced within the orbitofrontal cortex (p = .009), insula (p = .018), superior temporal gyrus (p = .019), parietal cortex (p = .026), medial and inferior temporal gyrus (p = .032), and superior frontal gyrus (p = .040). The voxel-based analysis revealed no significant clusters after rigorous FWE correction.Fig. 1Migraine patients have lower neocortical 5-HT~4~ receptor binding than controls (0.60 ± 0.09 vs. 0.67 ± 0.05, p = .024) after adjusting for covariates (5-HTTLPR status, age, and sex). Black bars indicate mean ± SD. The difference remained after exclusion of subject 15 (the patient with the lowest BP~ND~) (0.63 ± 0.06 vs. 0.68 ± 0.05, p = .038).Fig. 1

3.3. Associations with migraine characteristics {#s0055}
-----------------------------------------------

We found no associations between neocortical 5-HT~4~ receptor binding and attack frequency (slope estimate −0.017, CI: \[−0.081;0.047\], p = .56), years with migraine (slope estimate 0.003, CI: \[−0.007;0.012\], p = .53), or days since last attack (slope estimate 0.002, CI: \[−0.003;0.007\], p = .40).

4. Discussion {#s0060}
=============

The key finding of this study is that between attacks, migraine patients have lower 5-HT~4~ receptor binding within neocortex compared to controls. Our post hoc ROI analysis showed that this difference was most pronounced within the orbitofrontal, parietal, temporal and insular cortices, but no significant clusters were found when using a whole brain voxel-based analysis. This discrepancy is probably due to the conservative statistical method applied to the voxel-based analysis (p-value threshold of p \< .001 at voxel level, and correction for multiple comparisons using FWE) and due to the large whole-brain search volume. The latter was applied in order to detect any possible subcortical differences. Further, the detected difference between migraine patients and healthy controls was rather small, around 10%. This is, however, in line with previous studies finding significant differences in 5-HT~4~ receptor binding between groups differing with regards to intervention, genes or disease. Thus, a 5.2% decrease was found after 3 weeks of fluoxetine intervention ([@bb0085]), BDNF met-carriers were shown to have 7% higher neocortical binding relative to val/val-carriers, whereas 5-HTTLPR S-carriers had 7% lower binding compared to LL homozygotes ([@bb0070], [@bb0065]), and lastly, in Alzheimer\'s patients, PIB-positive patients had 13% higher binding compared to PIB-negative patients ([@bb0135]).

Although an acute increase in brain 5-HT levels does not affect \[^11^C\]SB207145 BP~ND~ ([@bb0150]), we took great care to ensure that all included patients were scanned during an attack-free interval (migraine free 48 h before and after scan) to exclude possible effects of attack related changes in brain 5-HT levels on 5-HT~4~ receptor binding. However, inclusion of the three subjects who reported to have a migraine attack within 48 after the scan did not change our results (p = .024). Furthermore, to reduce the possibility of variability in \[^11^C\]SB207145 binding due to diurnal 5-HT variations, we scanned all patients at the same time of the day (±1 h). Since we found no difference in grey matter volume between patients and controls within neocortex this is likewise not thought to affect the magnitude of 5-HT~4~ receptor binding. Lastly, the low 5-HT~4~ receptor binding could reflect changes in affinity of the 5-HT~4~ receptor in migraine patients. However, in colliculi neurons desensitization of the 5-HT~4~ receptor is caused by a loss of binding sites after continued 5-HT exposure ([@bb0015]). Thus, we interpret our findings of low \[^11^C\]SB207145 binding to reflect low neocortical density of the 5-HT~4~ receptor in migraine patients.

The low neocortical 5-HT~4~ receptor density in patients could be explained by repeated surges of 5-HT during migraine attacks -- causing an on average higher brain 5-HT level with subsequent downregulation of the cerebral 5-HT~4~ receptor. In support of this, our post hoc analysis identified lower 5-HT~4~ receptor binding in several regions implicated in migraine attacks; e.g. functional neuroimaging studies reported increased activation of insula, the prefrontal cortex and the temporal lobe during attacks compared to the attack free interval ([@bb0010]; [@bb0260]). Moreover, both insula and the orbitofrontal cortex are involved in pain modulation ([@bb0240]). However, we found no direct association between 5-HT~4~ receptor binding and migraine history (years), attack frequency (number per month) or days since the last migraine attack. It would be interesting to investigate whether duration of attack combined with frequency -- as a measure of hours with pain pr. month -- is associated with 5-HT~4~ receptor binding, but this analysis would have required a detailed, prospective headache diary. In addition, we cannot rule out a possible relationship between migraine severity and brain 5-HT levels in high frequency or chronic migraine. Future studies should include this patient group to investigate further whether the low 5-HT~4~ receptor density is a consequence of repeating migraine attacks.

Alternatively, the low neocortical 5-HT~4~ receptor density may reflect high brain 5-HT levels in migraine patients in the attack free interval. This interpretation challenges the longstanding belief that migraine patients have low brain 5-HT levels between attacks. To date, electrophysiological studies have provided the most substantial evidence for the 5-HT deficiency hypothesis ([@bb0040]). Migraine patients between attacks showed a lack of habituation of visual evoked potentials (VEP) ([@bb0005]) and an increased intensity dependence of auditory evoked potentials (AEP) ([@bb0250]), both thought to reflect low brain 5-HT levels ([@bb0190]; [@bb0265]). However, most of these studies were unblinded and did not report time to the next migraine attack. In addition, the findings were not reproduced in other studies ([@bb0160]; [@bb0185]). In the current study, all included migraine patients had been migraine free for 48 h before and after the scan and all data analyses were conducted by an investigator who was blinded to diagnoses and clinical data.

In addition to electrophysiological studies, some PET studies have suggested that brain 5-HT levels are low in migraine patients, but the results have been inconsistent. In a 5-HT~1A~-receptor PET neuroimaging study, higher cortical BP~ND~ in migraine patients compared to controls was interpreted as reflecting low brain 5-HT levels ([@bb0120]). However, the 5-HT~1A~ receptor radioligand, \[^18^F\]MPPF, is not convincingly sensitive to endogenous 5-HT levels in humans ([@bb0170]). One study reported a higher brain 5-HT synthesis capacity in migraine patients without aura when using α-\[11 C\]methyl-[l]{.smallcaps}-tryptophan as a surrogate marker of brain 5-HT synthesis capacity ([@bb0035]). This was interpreted as being consistent with a high 5-HT turnover and thus, low brain 5-HT levels. Interestingly, in another study using the same method, findings of a low cortical 5-HT synthesis capacity in migraine patients was likewise interpreted as reflecting low cortical 5-HT levels ([@bb0180]). Taking the limitations of these studies ([@bb0035]; [@bb0180]) into account (the reliability of α-\[11 C\]methyl-[l]{.smallcaps}-tryptophan as a surrogate marker of brain 5-HT synthesis capacity has been questioned ([@bb0195])), one might speculate whether a low 5-HT synthesis capacity could indeed reflect high 5-HT levels -- as found in the current study -- due to a negative feedback regulation on 5-HT synthesis. On the other hand, a high synthesis capacity may potentially lead to high 5-HT levels. In further support of our findings, high brain 5-HT levels in migraine patients between attacks may, at least partly, explain, why selective 5-HT reuptake inhibitors are not efficient as migraine prophylaxis ([@bb0020]).

4.1. Possible migraine-inducing mechanisms of serotonin {#s0065}
-------------------------------------------------------

Serotonergic agents such as m-chlorophenylpiperazine (m-CPP) ([@bb0110]), reserpine ([@bb0045]), and fenfluramine ([@bb0205]) induce migraine attacks more frequently in migraine patients than in controls, and most likely via increasing brain 5-HT levels ([@bb0165]). Since our data suggest the presence of increased brain 5-HT levels in migraine patients between attacks, we propose that migraine patients could be more susceptible to additional acute increases in 5-HT, which lead to migraine induction.

5-HT has generally been considered an inhibiting agent of pain and is one of the major neurotransmitters of the descending pain-inhibition pathway ([@bb0220]). In vitro, 5-HT exerts an antinociceptive effect in the trigeminal system ([@bb0105]) and in healthy animals 5-HT inhibits pain ([@bb0245]). However, recent preclinical studies have shown that 5-HT may be involved in pain facilitation as well ([@bb0025]). In 5-HT depleted rats, the acute pain reaction was intact but pain behavior in the second phase after formalin injection was attenuated. In addition, in persistent pain models 5-HT depleted rats exhibited a decrease in thermal hyperalgesia and mechanical allodynia ([@bb0255]). These pathophysiological-dependent properties of 5-HT may be due to the complex role of the different 5-HT receptor subtypes: The 5-HT~1~ and 5-HT~3~ receptors are generally considered antinociceptive, whereas the 5-HT~2A~ and the 5-HT~7~ receptors are considered pronociceptive ([@bb0245]). Thus, 5-HT may be both pro- and antinociceptive depending on receptor type, affinity and concentration ([@bb0215]). Interestingly, low density of the antinociceptive 5-HT~1B~ receptor was recently found in pain modulating regions in migraine patients between attacks ([@bb0055]). In light of our present findings we therefore speculate that the pathophysiology of migraine includes an imbalance in the pain modulating system caused by high interictal brain 5-HT levels and changes in expression of different 5-HT receptor subtypes, resulting in loss of inhibition and enhancement of pain facilitation.

4.2. Limitations {#s0070}
----------------

Even though several studies have corroborated the inverse relationship between 5-HT~4~ receptor binding and brain 5-HT levels ([@bb0085]; [@bb0115]), the method used in the present study is still an indirect measure of brain 5-HT levels. In addition, we cannot rule out that the effect of migraine status on the 5-HT~4~ receptor is specific for this receptor, and not due to changes in brain 5-HT levels.

5. Conclusions {#s0075}
==============

Migraine patients have low neocortical 5-HT~4~ receptor binding. Since pharmacological studies of 5-HT~4~ receptor binding suggest an inverse relationship with brain 5-HT levels, this most likely indicates higher brain 5-HT levels in migraine patients compared to controls. Our results, therefore, support the involvement of the serotonergic system in migraine pathophysiology, but are in contrast with the current hypothesis that migraine is a syndrome of low brain 5-HT levels. Future studies must explore whether our observation is due to high brain 5-HT levels between attacks, predisposing to migraine, or is the result of recurring migraine attacks with surges of 5-HT.
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